🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Alcohol is broken down by the body into acetaldehyde, which induces DNA damage. In 2009, IARC classed acetaldehyde included in or generated endogenously from alcoholic beverages as a Group 1 human carcinogen. #CancerPreventionActionWeek #bowelcancer #HIPEC #CombatCancer

Great news for the HIVEC-HEAT trial for Combat Medical HIVEC® with mitomycin medac for BCG-unresponsive non-muscle-invasive bladder cancer! #medicalinnovation #HIVEC #CombatCancer

A new study has found a modest but significant association between consumption of beer and spirits and an increased risk of pancreatic cancer, regardless of sex and smoking status. Find out more: doi.org/10.1371/journa… #HIPEC #pancreaticcancer #CombatCancer

In a recent study, drinkers with high daily intake of alcohol and high drinking frequency have the greatest risk of #colorectalcancer, suggesting that total alcohol intake is the critical factor. doi.org/10.1093/jnci/d… #CancerPreventionActionWeek2025 #HIPEC #CombatCancer

Breaking news! The FDA has just given "breakthrough device designation" to a new urine test for #bladdercancer, based on analysis of volatile organic compounds using gas chromatography-mass spectrometry and AI. #medicalinnovation #HIVEC #HIVECHEAT #CombatCancer

This month in the UK, thousands of people will be taking part in Pancreatic Cancer UK's Big Step Forward. The aim is to help transform the future for those affected by #pancreaticcancer by walking their chosen route to raise awareness and funding for research. #HIPEC #CombatCancer

Did you know that HIPEC with gemcitabine administered by Combat PRS+ has been found to significantly reduce locoregional recurrence in #PancreaticCancer? #HIPEC #TheBigStepForward2025 #CombatCancer

New-onset diabetes increases #pancreaticcancer risk by 6-8x. A new study suggests MRI may aid early detection. Currently, only 20% are diagnosed at stage 1, when the 5-year survival rate is 44%. 👉doi.org/10.1210/clinem… #bigstepforward2025 #HIPEC #CombatCancer

Our interview series with leading clinicians in urology & surgical oncology covers treatments and future directions in bladder, colorectal, ovarian and pancreatic cancer – all areas where we are making a difference with our #HIVEC® and #HIPEC treatments. bit.ly/3RPaJOt

The HIVEC-HEAT phase 3 trial will assess the effectiveness of our hyperthermic intravesical chemotherapy (HIVEC®) treatment with 80mg mitomycin medac as an alternative to radical cystectomy in BCG-unresponsive, NMIBC. #medicalinnovation #HIVEC #bladdercancer #CombatCancer

The open-label HIVEC-HEAT phase 3 trial will cover up to 25 UK sites, with a minimum of 5 participants recruited per year for most sites. There is no randomisation – it’s difficult to randomise against cystectomy. #medicalinnovation #HIVEC #bladdercancer #HIVECHEAT #CombatCancer

The HIVEC-HEAT phase 3 trial has 2 sub-studies: carcinoma in situ (n=123) & without carcinoma in situ (n=115), total n=238. Patients will have 40mg MMC medac for 1 hr using Combat BRS #HIVEC® for 15 recirculations over 1 yr & follow-ups at 15, 18, 21, 24 mths. #bladdercancer

Everything you need to know about the HIVEC-HEAT trial for BCG-unresponsive NMIBC, using our Combat BRS hyperthermic technology - enjoy! #medicalinnovation #HIVEC #CombatCancer

Pleased to be showcasing the capabilities of our Combat PRS+ CO2 agitation system for #HIPEC, together with our partner Nipro Colombia at the 1st Columbian Surgical Oncology Congress in Bogota. #medicalinnovation #colorectalcancer #ovariancancer #pancreaticcancer #CombatCancer

The COMBAT PRS+ is the only peritoneal recirculation system with CO2 agitation to optimise #HIPEC. Automatic agitation ensures homogenous drug & thermal distribution throughout the abdominal cavity and peritoneal surfaces to maximise safety and patient outcomes. #CombatCancer

Closed and laparoscopic #HIPEC techniques using controlled intra-abdominal pressure via the COMBAT PRS+ (peritoneal recirculation system) improve drug penetration into the tumour and peritoneum. #medicalinnovation #coloncancer #ovariancancer #pancreaticcancer #CombatCancer

The phase 3 trial HIPECT4 RCT* found that adding COMBAT PRS+ #HIPEC with MMC to cytoreductive surgery significantly reduced the risk of locoregional recurrence in advanced colorectal cancer. *Arjona-Sánchez et al, JAMA Surgery, 2023 #colorectalcancer #CombatCancer

Our interview series with leading clinicians in urology & surgical oncology covers treatments and future directions in bladder, colorectal, ovarian and pancreatic cancer – all areas where we are making a difference with our #HIVEC® and #HIPEC treatments. bit.ly/3RPaJOt

A new review in Cureus* of the BladderPath trial suggests that multiparametric MRI represents the most robust prospective evidence supporting an imaging-first diagnostic approach in #bladdercancer staging. 👉 bit.ly/4kTwRTy #HIVEC #CombatCancer

Compared to the standard #bladdercancer diagnostic pathway (white-light cystoscopy + TURBT), mpMRI leads to a median 45-day reduction time to treatment initiation & significantly fewer repeat procedures. 👉bit.ly/4kTwRTy #HIVEC #CombatCancer